The A.R.R.E.S.T.® Contact Lens Study

Prospective, Controlled, Randomised, Contralateral Wear, Dispensing Trial to Assess the Efficacy of Contact Lenses Using A.R.R.E.S.T.® Technology

The goal of this clinical trial is to learn if contact lenses using Active Reconfiguration in Retinal Encoding of Spatio-Temporal (A.R.R.E.S.T.®) signal technology works to slow down the rate of myopia progression compared to single vision contact lenses in myopic children. The main questions it aims to answer are:

Do contact lenses using A.R.R.E.S.T.® technology slow down the rate of axial length growth? Do contact lenses using A.R.R.E.S.T.® technology slow down the rate of increase in myopic refractive error?

Researchers will compare contact lenses using A.R.R.E.S.T.® technology to a single vision contact lens.

Participants will:

Be randomly allocated to wear either contact lenses using A.R.R.E.S.T.® technology or single vision contact lenses.

Visit the clinic on seven occasions over a 12 month period.

Study Overview

• Status: Active, not recruiting
• Conditions: Myopia; Myopia Progression
• Intervention / Treatment: Device: Single-vision contact lens; Device: A.R.R.E.S.T.® contact lens

Detailed Description

The aim of this clinical trial is to compare the rate of myopia progression as measured by change from dispensing, in axial length and the change from Baseline in the spherical equivalent cycloplegic autorefraction between a contact lens using A.R.R.E.S.T.® technology (test) and a single vision contact lens (control). Myopic children (7-15 years of age) will be randomly allocated to wear either test or control.

The overall trial duration, including follow-up period, is expected to be approximately 18 months. Each participant's duration is expected to be approximately 12 months.

The visits are Baseline, 1 week, 1 month, 3 months, 6 months, 9 months, and 12 months.

All procedures performed at these visits are standard, non invasive clinical tests.

• Study Type: Interventional
• Enrollment (Estimated): 80
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Zhejiang
    • Wenzhou, Zhejiang, China, 325000
      • Wenzhou Medical University
• Malaysia
  • Kuala Lumpur, Malaysia, 50300
    • Optometry Clinic, Faculty of Health Science, Universiti Kebangsaan Malaysia

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria

• Be between 7 to 15 years old inclusive at time of enrolment.

• Have:

  • Read the Informed Assent.
  • Been explained the Informed Assent.
  • Indicated an understanding of the Informed Assent.
  • Signed the Informed Assent.

• Have their parent / legal guardian.

  • Read the Informed Consent.
  • Been explained the Informed Consent.
  • Indicated an understanding of the Informed Consent.
  • Signed the Informed Consent.
• Along with their parent/legal guardian, be capable of comprehending the nature of the study and be willing to adhere to the study requirements.
• Along with their parent/legal guardian, agree to maintain the visit and prescribed wearing schedule.
• Agree to wear the study contact lenses for a minimum of 5 days/week, 6 hours/day on days lenses are worn but not > 16 hours per day, and to remove lenses at night (i.e., daily wear only with no contact lens wear during sleep), for the duration of the study and to inform the investigator if their schedule is interrupted. Wearing time can be modified by the investigator for health reasons.
• Be in good general health, based on parent's/legal guardian's knowledge.
• Have best-corrected high contrast visual acuity of 0.10 logMAR (Snellen: 20/25, 6/7.6; Decimal: 0.80) or better in each eye.

• Meet the following criteria determined by cycloplegic autorefraction at Baseline:

  • -4.00 D ≤ spherical equivalent ≤ 0.75 D
  • -1.00 DC ≤ astigmatic component ≤ 0 DC

• Participants who fail astigmatism criterion with autorefraction pass astigmatism criterion if ≥ 0.75 D is measured with subjective refraction.

  • |Spherical equivalent anisometropia| ≤ 1.00 D.

Exclusion Criteria

• Participant in another study within 30 days prior to this study.
• Current or prior use of interventions intended for myopia control, including but not limited to:

• Optical devices:

  • Bifocal / multifocal spectacles.
  • Bifocal / multifocal contact lenses.
  • Orthokeratology.

• Pharmacological agents:

  • Atropine with a concentration > 0.01%.
  • Participants who have previously used 0.01% atropine are eligible for this study provided they agree not to use 0.01% atropine for at least 30 days before baseline and at any time during the study.
  • Pirenzepine.

• Participant born earlier than 30 weeks or weighed < 1500 g at birth.

  o A verbal report from the participant's parent / legal guardian is sufficient.

• Habitual use of a systemic or topical medication that may alter normal ocular findings / is known to affect a participant's ocular health / physiology either in an adverse or beneficial manner at enrolment and / or during the clinical trial.
• A known allergy to sodium fluorescein, benoxinate, proparacaine, tropicamide, or cyclopentolate.
• A known corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections, or any other recurrent ocular infections.
• Strabismus as determined by cover test at distance (≥ 3 m) or near (40 cm) while wearing distance correction under non-cycloplegic conditions.

• Known ocular or systemic disease, such as but not limited to:

  • Diabetes.
  • Graves' disease.
  • Glaucoma.
  • Uveitis.
  • Scleritis.
  • Auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome, and systemic lupus erythematosus.
  • Any ocular, systemic, or neuro-developmental conditions that could influence refractive development, such as but not limited to:
  • Persistent pupillary membrane.
  • Vitreous haemorrhage.
  • Cataract.
  • Central corneal scarring.
  • Eyelid haemangiomas.
  • Marfan's syndrome.
  • Down's syndrome.
  • Ehler's-Danlos syndrome.
  • Stickler's syndrome.
  • Ocular albinism.
  • Retinopathy of prematurity.
  • Keratoconus or irregular cornea.

• Biomicroscopic that contraindicate contact lens, such as but not limited to:

  • Neovascularisation or ghost vessels ≥ 1.5 mm in from limbus.
  • Any active anterior segment disease that contraindicates safe contact lens wear.
  • Clinically significant giant papillary conjunctivitis.
  • Clinically significant abnormalities of the anterior segment, lids, conjunctiva, sclera, or associated structures.
  • Allergic or seasonal conjunctivitis if the investigator believes it could significantly interfere with maintaining a specified wearing schedule.
• The investigator may, at their discretion, exclude anyone who they believe may not be able to fulfil the clinical trial requirements or it is believed to be in the participant's best interests.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Assigned Intervention 1; Single vision contact lens	Device: Single-vision contact lens; Standard single vision contact lens
Experimental: Assigned Intervention 2; A.R.R.E.S.T.® contact lens	Device: A.R.R.E.S.T.® contact lens; Contact lens with edge pattern

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Axial Length	Difference in change from baseline in axial length between each test and control.	Baseline, then1 month, 3 months, 6 months, 9 months, and 12 months after baseline
Cycloplegic spherical equivalent autorefraction	Difference in change from Baseline in cycloplegic spherical equivalent autorefraction between each test and control.	Baseline, then 6 months, and 12 months after baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Visual performance as measured by high contrast visual acuity at 6 m	Difference in visual acuity between each test and control.	Baseline, then 1 week, 1 month, 3 months, 6 months, 9 months, 12 months after baseline
Visual performance as measured by a non validated questionnaire based on a 1-10 numeric rating scale	Difference in subjective visual performance between test and control after a minimum wear of one month.	1 month, 3 months, 6 months, 9 months, 12 months after baseline

Collaborators and Investigators

• Sponsor: nthalmic Pty Ltd

Study record dates

Study Major Dates

• Study Start (Actual): July 6, 2025
• Primary Completion (Estimated): June 1, 2028
• Study Completion (Estimated): June 1, 2028

Study Registration Dates

• First Submitted: March 10, 2025
• First Submitted That Met QC Criteria: March 13, 2025
• First Posted (Actual): March 14, 2025

Study Record Updates

• Last Update Posted (Actual): July 31, 2026
• Last Update Submitted That Met QC Criteria: July 29, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: axial length
• Additional Relevant MeSH Terms: Eye Diseases; Refractive Errors; Myopia
• Other Study ID Numbers: nthal2024-03

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: There is no plan to make IPD available to other researchers.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No